Financial Performance - Revenue increased by 3.9% to RMB 7,175,804 thousand compared to RMB 6,906,524 thousand in the same period last year[2] - EBITDA rose by 14.2% to RMB 2,231,943 thousand from RMB 1,953,790 thousand year-over-year[2] - Profit before tax grew by 18.0% to RMB 1,901,702 thousand compared to RMB 1,612,155 thousand in the previous year[2] - Net profit attributable to the company's owners increased by 16.1% to RMB 1,491,404 thousand from RMB 1,284,496 thousand[2] - Basic earnings per share rose by 16.1% to 82.08 RMB cents from 70.69 RMB cents[2] - Interim dividend per share increased by 33.3% to 16.0 RMB cents from 12.0 RMB cents[2] - Total revenue for the first half of 2024 reached RMB 7,175,804 thousand, a 3.9% increase from RMB 6,906,524 thousand in the same period last year[13][14] Revenue Breakdown by Product - Revenue from intermediate products increased to RMB 3,081,282 thousand, up 14.5% YoY from RMB 2,692,115 thousand[13][14] - Revenue from active pharmaceutical ingredients (API) rose to RMB 3,917,640 thousand, a 1.8% increase from RMB 3,849,116 thousand YoY[13][14] - Revenue from finished dosage products slightly decreased to RMB 2,397,777 thousand, down 1.6% from RMB 2,436,110 thousand YoY[13][14] Revenue Breakdown by Region - Revenue from China (including Hong Kong) grew to RMB 5,748,478 thousand, a 3.7% increase from RMB 5,544,083 thousand YoY[15] - Revenue from Europe decreased to RMB 411,566 thousand, down 4.6% from RMB 431,526 thousand YoY[15] - Revenue from India increased to RMB 376,958 thousand, up 13.6% from RMB 331,769 thousand YoY[15] Research and Development - Research and development expenses increased to RMB 446,800 thousand from RMB 338,678 thousand, reflecting a focus on innovation[4] - R&D expenditure increased significantly to RMB 446,800 thousand, up 31.9% from RMB 338,678 thousand YoY[13][14] Assets and Liquidity - Total assets increased to RMB 15,411,907 thousand from RMB 14,390,448 thousand, indicating growth in the company's asset base[5] - Cash and cash equivalents rose significantly to RMB 6,554,830 thousand from RMB 4,261,989 thousand, reflecting improved liquidity[5] - Total equity increased to RMB 13,573,883 thousand from RMB 12,747,618 thousand, showing growth in shareholder value[6] - The company's cash and bank balances increased to RMB 7,321,900,000 as of June 30, 2024, up from RMB 5,234,200,000 on December 31, 2023[42] - Total assets grew to RMB 22,826,100,000 as of June 30, 2024, compared to RMB 21,017,200,000 at the end of 2023[42] - Net current assets rose to RMB 7,733,500,000 as of June 30, 2024, from RMB 7,160,500,000 on December 31, 2023[42] - The company's net cash and bank balances after deducting bank borrowings and trade payables stood at RMB 3,265,100,000 as of June 30, 2024, up from RMB 1,755,500,000 at the end of 2023[42] - The company's current ratio was 2.04 as of June 30, 2024, slightly down from 2.08 on December 31, 2023[42] Debt and Borrowings - The company's interest-bearing borrowings increased to RMB 2,439,400,000 as of June 30, 2024, up from RMB 1,496,900,000 at the end of 2023[42] Government Subsidies and Foreign Exchange - Government subsidies surged to RMB 100,709 thousand, a 189.3% increase from RMB 34,809 thousand YoY[16] - Net foreign exchange gains decreased to RMB 30,773 thousand, down 39.3% from RMB 50,682 thousand YoY[18] Legal and Environmental Initiatives - The company is involved in a legal case seeking to recover RMB 340,000,000 from Chengdu Evergrande, with a partial judgment of RMB 136,300,000 awarded[45] - The company's Inner Mongolia subsidiary launched a salt separation and acid-base conversion project, expected to reduce solid waste by 6,600 tons annually and cut CO2 emissions by 45,000 tons[46] Strategic Focus - The company is focusing on consolidating core industry advantages and enhancing R&D innovation capabilities in response to China's healthcare reform[47] Employee Count - The company employs approximately 15,000 staff in Hong Kong and Mainland China, unchanged from December 31, 2023[44]

Investment Rating - The report assigns a "Buy" rating to the company with a target price of HKD 11.97, indicating a potential upside of 30.0% from the current price of HKD 9.21 [1][12]. Core Insights - The company has demonstrated rapid revenue growth, with a 2023 revenue of RMB 137.39 billion, representing a year-on-year increase of 21.2%. The net profit attributable to shareholders reached RMB 27 billion, up 70.9% year-on-year, and the dividend per share increased by 108% to RMB 0.52 [6][9]. - The company is focusing on the diabetes and weight management sectors, with significant progress in new product development. A new GLP-1/GIP/GCG triple receptor agonist has received clinical trial approval in the U.S. and is expected to enter the Chinese market soon [7][10]. - The company plans to continue increasing its R&D investment, which reached RMB 8.08 billion in 2022, a 36% increase from the previous year. The revenue projections for 2024-2026 are RMB 151 billion, RMB 160.3 billion, and RMB 169.7 billion, respectively [10][12]. Financial Summary - In 2023, the company reported a total revenue of RMB 137.39 billion, with a gross profit margin of 46.11% and a net profit margin of 19.66% [14]. - The company’s total assets amounted to RMB 210 billion, with a net asset value of RMB 127 billion. The earnings per share (EPS) for 2023 was RMB 1.49, with projections of RMB 1.58, RMB 1.70, and RMB 1.80 for 2024, 2025, and 2026, respectively [2][14]. - The company’s market capitalization is approximately HKD 167 billion, with a total share count of 1.817 billion shares [2].

欢迎各位投资者参加华安医药联合录影中举办的夏季现场策略会 本场是上市公司联邦之要的一个交流那么我们也是很荣幸的邀请到了公司领导艾尔莫总和我们进行一个交流和分享那今天的交流主要是分为公司介绍和QA两个环节那首先呢有请公司领导艾尔莫总用那个二十到三十分钟的时间对公司的一个经营情况最新的一个进展做一个讲解接下来我们把时间交给莫总 好的,谢谢刘总各位好,我是联邦指导的IR Mercy接下来我会为各位介绍一下集团2023年的一个整体的业绩情况以及2024年现在的一个最新的一个进展 诶 莫总您那边好像开了静音我们这边听不到您那边的那个声音诶 哈喽 现在可以了吗现在可以了 好的哦 好好好 不好意思那我重新开始吧好的好的嗯 各位小伙好,我是联邦之鸟的IR Mercy接下来呢,我会为各位去回顾一下我们2023年全年的一个业绩情况以及目前我们现在最新的各个板块的一个业务进展首先呢,我们简单的回顾一下2023年的业绩情况2023年呢 集团整体取得了非常令人满意的成绩其中营业额取得了同比超过20%的增长达到了人民币137亿元拥有人应价屹立同比大幅增长接近71%达到了人民币27亿元2023年度全年累计派息52分其中末期股息人民币每股2 ...

ur 聯邦制藥國際控股有限公司 (於開曼群島註冊成立之有限公司) (股份代號: 3933) 度 100 讓生命更有價值 [•] [•] 本集團創立於一九九零年，主要從事藥品的研發、生產及銷售，是中國領先的綜合性製藥企 業之一。二零零七年六月十五日於香港聯交所主板上市（股份代號：3933）。現時，本集團為 恒生綜合指數系列的成份股之一，明晟(MSCI)ESG評級A級，位居同業領先。 歷經三十餘年的高速發展，本集團從創立初期以抗生素為主導的產品結構，現已延伸至生 物製藥、動保用藥領域，並持續優化垂直整合的業務模式。目前擁有七家生產基地，產品涵 蓋醫藥中間體及原料藥、製劑產品、獸藥、藥用空心膠囊、醫療器械，銷售網路遍佈全球近 80個國家和地區。 本集團持續擴展藥物研究領域與國際化視野，多平台全面佈局協同發展，聚焦內分泌、代 謝、自身免疫、抗感染、眼科等領域，多款1類新藥已進入臨床試驗階段。截至目前，本集團 在研項目合計百餘項，取得專利超100項。 本集團將秉承「讓生命更有價值」的企業宗旨，緊跟國家發展戰略，持續推進產業創新升級， 為社會提供更多優質高效的產品及服務，全面助力中國醫藥產業衛生事業發展。 目錄 | -- ...

联邦制药（3933 HK）| 2024 年 4 月 2 日 香港股市 | 医药 联邦制药（3933 HK） 2023 年盈利超越预期，未来将稳健增长 2023 年盈利超越预期 公司 2023 年营业收入同比增长 21.2%至 137.4 亿元（人民币，下同），略超我们预期。2023 年海外市场中间体与原料药的需求显著回升，国内市场需求也逐步回暖，公司中间体与原料 药业务收入分别同比上涨 44.9%与 23.7%至 23.2 亿元及 64.0 亿元。与此同时，由于动保业务 下半年从主要客户牧原股份获得更多订单等原因，公司制剂业务收入同比增加 10.2%至 50.2 亿元。由于中间体及原料药产品价格上涨等原因，公司毛利率从 43.8%提高至 46.1%。公司销 售费用率从 2022 年的 14.7%降低至 11.6%，导致股东净利润同比增加 70.9%至约 27.0 亿元， 超出预期 18.8%。 预计 2024-26E 收入将平稳增长 考虑到 2023 年收入略超预期，我们将 2024-25E 收入预测分别微升 0.05%、2.5%，预计 2023- 26E 收入 CAGR 为 6.9%，基于：1）随着国内医药 ...

中间体/原料药表现突出，GLP-1管线丰富 联邦制药（3933.HK）/医药 证券研究报告/公司点评 2024年4月8日 生物 [Table_Industry] [评Ta级ble：_T买itle入] （维持） [公Ta司ble盈_F利in预anc测e]及 估值 市场价格：9.20港元 指标 2022A 2023A 2024E 2025E 2026E 营业收入（百万元） 11353 13754 15047 15806 16592 分析师：祝嘉琦 增长率yoy% 16.66% 21.15% 9.40% 5.04% 4.97% 执业证书编号：S0740519040001 净利润（百万元） 1581 2701 2870 2995 3115 电话：021-20315150 增长率yoy% 60.01% 70.85% 6.23% 4.36% 4.00% 每股收益（元） 0.87 1.49 1.58 1.65 1.71 Email：zhujq@zts.com.cn 每股现金流量 1.12 0.00 2.96 2.93 3.35 分析师：张楠 净资产收益率 0.16 0.23 0.20 0.18 0.15 执业证书编号：S0 ...

Financial Performance - Revenue for 2023 reached RMB 13,739,879,000, a 21.2% increase compared to 2022[2] - Net profit attributable to the company's owners surged by 70.9% to RMB 2,701,400,000[4] - The company's EBITDA rose by 50.6% to RMB 3,976,692,000 in 2023[2] - The company's pre-tax profit grew by 66.6% to RMB 3,344,148,000[2] - Revenue for 2023 reached RMB 13,739.879 million, a 21.2% increase from RMB 11,334.262 million in 2022[12] - Net profit for 2023 was RMB 2,700.845 million, up 70.8% from RMB 1,581.023 million in 2022[12] - Earnings per share for 2023 increased to RMB 148.67 cents, compared to RMB 86.89 cents in 2022[12] - Profit before tax for 2023 was RMB 3,344,148 thousand, up from RMB 2,006,766 thousand in 2022[22][24] - Revenue for the year ended December 31, 2023, was approximately RMB 13,739.9 million, an increase of 21.2% year-over-year[43] - EBITDA for the year was approximately RMB 3,976.7 million, up 50.6% year-over-year[43] - Net profit attributable to shareholders was RMB 2,701.4 million, a 70.9% increase year-over-year[43] R&D and Innovation - R&D investment increased by 36.2% to RMB 808,300,000 in 2023[5] - The company's GLP-1 drug UBT251 injection received clinical trial approvals in both China and the US[5] - Research and development costs rose to RMB 757,248 thousand in 2023, compared to RMB 593,598 thousand in 2022, reflecting increased investment in innovation[27] - The company invested RMB 808.3 million in R&D, a 36.2% increase year-over-year, with 39 new human drug products under development, including 19 Class 1 new drug projects[46] Global Expansion and Market Reach - The company's upstream products now cover nearly 80 countries and regions globally[6] - Revenue from China (including Hong Kong) increased to RMB 11,124,265 thousand in 2023, compared to RMB 8,962,740 thousand in 2022[25] - Revenue from Europe grew to RMB 783,732 thousand in 2023, up from RMB 631,282 thousand in 2022[25] - Revenue from India reached RMB 673,922 thousand in 2023, compared to RMB 556,336 thousand in 2022[25] - Revenue from South America increased to RMB 340,391 thousand in 2023, up from RMB 297,594 thousand in 2022[25] - Overseas sales of intermediate products and APIs reached RMB 2,615.6 million, accounting for 19.0% of total sales[44] Product Segments and Revenue Breakdown - Revenue from intermediate products increased to RMB 5,753,101 thousand in 2023, up from RMB 4,317,709 thousand in 2022[22][24] - Revenue from active pharmaceutical ingredients (API) rose to RMB 7,392,185 thousand in 2023, compared to RMB 6,044,904 thousand in 2022[22][24] - Revenue from finished dosage products grew to RMB 5,023,821 thousand in 2023, up from RMB 4,560,331 thousand in 2022[22][24] - Total revenue for 2023 reached RMB 13,739,879 thousand, a significant increase from RMB 11,334,262 thousand in 2022[22][24] - Intermediate products and active pharmaceutical ingredients (API) segments saw revenue increases of 33.2% and 22.3%, respectively, with profit increases of 116.0% and 102.7%[43] Capital and Asset Management - Total assets as of December 31, 2023, were RMB 14,390.448 million, up from RMB 11,946.598 million in 2022[13] - Non-current assets grew to RMB 7,229.979 million in 2023, compared to RMB 6,464.679 million in 2022[13] - Current assets increased to RMB 13,787.201 million in 2023, up from RMB 12,514.946 million in 2022[13] - The company's equity attributable to owners rose to RMB 12,734.778 million in 2023, from RMB 10,608.086 million in 2022[15] - The company invested RMB 1,143,439 thousand in property, plant, and equipment in 2023, a significant increase from RMB 701,986 thousand in 2022[34] - Trade receivables and bills receivable totaled RMB 6,314,480 thousand in 2023, up from RMB 4,911,704 thousand in 2022, with credit loss provisions of RMB 12,459 thousand for trade receivables[35] - The company typically offers trade customers a credit period of 45 to 120 days, with selected customers potentially receiving extended credit based on trade volume and historical settlement records[36] - The aging analysis of trade receivables shows that 0 to 30 days receivables amounted to RMB 920,770 thousand in 2023, down from RMB 1,026,413 thousand in 2022[37] - Trade payables and other payables totaled RMB 2,238,152 thousand in 2023, with supplier financing arrangements accounting for RMB 1,981,929 thousand[39] - Capital commitments for the acquisition of property, plant, and equipment amounted to RMB 989,055 thousand in 2023, up from RMB 355,691 thousand in 2022[40] - The company pledged assets worth RMB 22,440 thousand in property, plant, and equipment and RMB 972,249 thousand in bank deposits as collateral for bank credit in 2023[41] - The company's current assets increased to RMB 13,787,200,000 in 2023 from RMB 12,514,900,000 in 2022, with net current assets rising to RMB 7,160,500,000 from RMB 5,481,900,000[49] - The current ratio improved to 2.08 in 2023 compared to 1.78 in 2022[49] - Total assets grew to RMB 21,017,200,000 in 2023 from RMB 18,979,600,000 in 2022, while total liabilities decreased to RMB 8,269,600,000 from RMB 8,370,200,000[49] - Equity attributable to owners of the company increased to RMB 12,734,800,000 in 2023 from RMB 10,608,100,000 in 2022[49] - Net cash and bank balances after deducting borrowings and supplier financing arrangements stood at RMB 1,755,500,000 in 2023, up from RMB 1,394,600,000 in 2022[49] - The company held RMB 5,234.2 million in bank deposits, cash, and cash equivalents as of December 31, 2023[48] - The company's interest-bearing borrowings were RMB 1,496.9 million, all due within five years, with RMB 23.9 million in fixed-rate loans and RMB 1,473.0 million in floating-rate loans[48] Dividends and Shareholder Returns - The company's total dividend for 2023 increased by 108% to RMB 52 cents per share[2] - Dividends declared for 2023 totaled RMB 581,448 thousand, up from RMB 272,636 thousand in 2022, reflecting higher interim and special dividends[32] - The company proposed a final dividend of RMB 28 cents per share and a special dividend of RMB 12 cents per share for 2023, totaling RMB 726,811 thousand[32] Employee and Social Responsibility - The company added over 5,000 jobs in the past decade, contributing to social responsibility efforts[10] - The company launched a stock incentive plan in 2023 to align employee interests with corporate value[10] - The company is committed to green factory construction, supporting national carbon neutrality goals[10] - Employee costs, including salaries and benefits, rose to RMB 1,648,745 thousand in 2023, compared to RMB 1,397,006 thousand in 2022[31] - The company employed approximately 15,000 staff in Hong Kong and Mainland China as of December 31, 2023, compared to 14,000 in 2022[51] - The company granted a total of 12,096,900 reward shares to selected participants under the 2023 Share Award Scheme[52] Legal and Contingent Liabilities - The company won a lawsuit against Chengdu Evergrande, with the court ordering payment of approximately RMB 136,300,000, though the company has appealed the decision[53] - The company has no significant contingent liabilities as of December 31, 2023[52] Financial Costs and Taxation - Financial costs decreased to RMB 66,896 thousand in 2023 from RMB 81,595 thousand in 2022, primarily due to lower borrowing interest[28] - Tax expenses increased to RMB 643,303 thousand in 2023, up from RMB 425,743 thousand in 2022, mainly due to higher corporate income tax in China[29] - The company's financial costs decreased by 18.0% to RMB 66.9 million, with net cash and bank balances of RMB 1,755.5 million as of December 31, 2023[47] Other Income and Expenses - Other income increased to RMB 212,475 thousand in 2023, up from RMB 165,817 thousand in 2022, driven by higher bank interest income and subsidy income[26] - Depreciation of property, plant, and equipment increased to RMB 536,303 thousand in 2023 from RMB 521,834 thousand in 2022[31] Treasury and Risk Management - The company maintains a treasury policy to monitor and manage currency exchange rate risks, using forward contracts as needed[50] Production and Infrastructure - The company launched the construction of the Zhuhai Lianbang Gaolan Port API project in November 2023[7] - The company's animal health business experienced rapid growth, with new production bases under construction in Inner Mongolia and Zhuhai[9] - The company's new production base in Zhuhai Gaolan Port, with a total construction area of 120,000 square meters, began construction in November 2023, aiming to enhance the automation and scale of API production[44]

E 聯邦制藥國際控股有限公司 (於開曼群島註冊成立之有限公司) (股份代號: 3933) 幸运 中 期 I u 讓 生 命 更 有 價 值 目錄 2 財務摘要 3 公司資料 | --- | --- | --- | --- | |-------|-------|-------|------------------------------| | | | | | | | | 4 | 簡明綜合財務報表審閱報告 | | | | 5 | 簡明綜合損益及其他全面收益表 | | | | 6 | 簡明綜合財務狀況表 | | | | 8 | 簡明綜合權益變動表 | | | | 9 | 簡明綜合現金流量表 | | | | 11 | 簡明綜合財務報表附註 | | | | 32 | 管理層討論與分析 | | | | 37 | 其他資料 | | | | | | 財務摘要 財務摘要 截至六月三十日止六個月 | --- | --- | --- | --- | |----------------------------------|---------------------------|---------------------------| ...

Financial Performance - Revenue for the six months ended June 30, 2023, was RMB 6,906,524 thousand, representing a 33.3% increase from RMB 5,181,925 thousand in the same period of 2022[2] - Profit before interest, tax, depreciation, and amortization (EBITDA) was RMB 1,953,790 thousand, up 71.2% from RMB 1,140,996 thousand year-on-year[2] - Profit attributable to owners of the company reached RMB 1,284,496 thousand, a significant increase of 104.0% compared to RMB 629,517 thousand in the previous year[2] - Basic earnings per share rose to RMB 70.69, reflecting a 104.6% increase from RMB 34.55[2] - The profit before tax for the period was RMB 1,612,155 thousand, reflecting strong operational performance[13] - The total segment profit for the six months ended June 30, 2023, was RMB 919,831 thousand, compared to RMB 826,954 thousand for the same period in 2022, showing a growth of approximately 11.2%[15] - The company reported a net foreign exchange gain of RMB 50,682 thousand for the six months ended June 30, 2023, compared to a loss of RMB 48,568 thousand in the same period of 2022[19] - The income tax expense for the six months ended June 30, 2023, was RMB 327,915,000, up from RMB 197,437,000 in the same period of 2022, reflecting a growth of 66.1%[21] - The financial cost for the company was approximately RMB 38,700,000, representing a year-on-year increase of 77.7%[42] Dividends - The interim dividend per share was declared at RMB 12.0, a 140.0% increase from RMB 5.0 in the prior period[2] - The company declared an interim dividend of RMB 0.12 per share for the six months ended June 30, 2023, totaling RMB 218,043,000, compared to RMB 0.05 per share totaling RMB 90,879,000 for the same period in 2022[26] - The total dividend declared for the year included a final dividend of RMB 0.14 per share and a special dividend of RMB 0.06 per share, totaling RMB 363,405,000 for the six months ended June 30, 2023, compared to RMB 181,757,000 for the same period in 2022[25] Assets and Liabilities - Total assets as of June 30, 2023, amounted to RMB 13,212,085 thousand, compared to RMB 12,514,946 thousand at the end of 2022[5] - Net current assets increased to RMB 6,148,352 thousand from RMB 5,481,919 thousand at the end of 2022[5] - Non-current liabilities decreased to RMB 1,174,610 thousand from RMB 1,337,167 thousand at the end of 2022[6] - The company's net asset value increased to RMB 11,531,617 thousand from RMB 10,609,431 thousand at the end of 2022[6] - The company's total liabilities decreased to approximately RMB 8,238,300,000 as of June 30, 2023, from RMB 8,370,200,000 as of December 31, 2022[44] Revenue Segmentation - The revenue from intermediates was RMB 2,692,115 thousand, while the revenue from APIs and formulations were RMB 3,849,116 thousand and RMB 2,436,110 thousand respectively, contributing to a total segment revenue of RMB 8,977,341 thousand[14] - The revenue from the Chinese market (including Hong Kong) was RMB 5,544,083 thousand, an increase from RMB 4,129,014 thousand in the previous year, reflecting a growth of approximately 34.4%[16] - Revenue from intermediates, active pharmaceutical ingredients, and formulations was approximately RMB 2,692,100,000, RMB 3,849,100,000, and RMB 2,436,100,000 respectively, with year-on-year increases of 37.2%, 34.6%, and 29.1%[38] - The intermediate and raw materials segment recorded external sales revenue of approximately RMB 1,047,400,000 and RMB 3,423,000,000, representing year-on-year increases of 41.4% and 34.1% respectively[39] - The formulation products segment achieved sales revenue of approximately RMB 2,436,100,000, a year-on-year increase of 29.1%[40] - Antibiotic products, including animal health products, recorded sales revenue of RMB 1,725,000,000, reflecting a year-on-year growth of 50.5%[40] Investments and Expenditures - The total expenditure on property, plant, and equipment for the six months ended June 30, 2023, was approximately RMB 395,085,000, an increase from RMB 281,759,000 in the same period of 2022, marking a rise of 40.3%[27] - The company invested RMB 350,300,000 in drug research and development, marking a year-on-year increase of 44.4%[41] - As of June 30, 2023, the company had capital expenditure commitments of RMB 497,212,000 for property, plant, and equipment[35] Corporate Governance and Management - The board emphasizes strong corporate governance as essential for protecting shareholder interests and enhancing group performance, adhering to the corporate governance code[51] - The company currently does not have a CEO, with plans to appoint one at an appropriate time[52] - The Audit Committee, composed of three independent non-executive directors, has reviewed the unaudited condensed consolidated financial statements for the six months ending June 30, 2023[53] Future Outlook - The company anticipates a recovery phase in the Chinese economy post-pandemic, with a focus on consolidating core industry advantages and enhancing cost control along the supply chain[49] Legal Matters - The company is involved in a lawsuit against Chengdu Evergrande, seeking to recover approximately RMB 340 million in unpaid receivables and related damages, with the first hearing held on February 21, 2023, and the second on June 6, 2023, currently awaiting a judgment[47] Shareholder Engagement - The board expresses gratitude to shareholders and partners for their support during the first half of 2023, highlighting the contributions of all employees[55]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依賴該等內容而 引致的任何損失承擔任何責任。 The United Laboratories International Holdings Limited 聯邦制藥國際控股有限公司 (於開曼群島成立之有限公司) (股份代號: 3933) 截至二零二三年六月三十日止六個月之 中期業績公告 財務摘要 | --- | --- | --- | --- | |----------------------------------|----------------------------------------------------|---------------------------|--------------| | | 截至六月三十日止六個月 \n二零二三年 \n人民幣千元 | 二零二二年 \n人民幣千元 | 上升 | | 收入 | 6,906,524 | 5,181,925 33.3% | | | 未計利息、稅項、折舊及攤銷前溢利 | 1,953,7 ...